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ABSTRACT 
 
Liquisolid technique is a novel technique. It is used to improve the 
dissolution rate of the poorly water soluble drugs like loperamide. The 
liquisolid compacts were prepared by using carrier, coating material & 
liquid medication. Liquisolid compacts   refer to the formulations that are 
formed by conversion of liquid drugs, drug suspension or solution in 
non-volatile solvents into dry, non-adherent, free flowing and 
compressible powder mixture. The crystallanity of the newly formulated 
drug and the interaction between excipients was examined by X-ray 
powder diffraction (XRD) and Fourier-transform infrared spectroscopy 
(FTIR). finally the increased dissolution rate of poorly water soluble drug. 
Loperamide is a Piperidine derivative, it is used in treatment of Anti 
diarrheal agent. 
 
  
Keywords: loperamide, liquisolid compacts, X-RD, FT-IR, dissolution 
profile. 
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INTRODUCTION 
1. DRUG DELIVERY SYSTEM  
  Dosage forms are also referred to as “Drug Delivery Systems” or 
“Finished Drug Products”. A drug delivery system (DDS) is defined as 
a formulation or a device that enables the introduction of a 
therapeutic substance into the body and improves its efficacy and 
safety by controlling the rate, time, and site of release of drugs in the 
body. The goal of any drug delivery system is to provide a therapeutic 
amount of drug in the proper site in the body to achieve promptly and 
then to maintain the desired drug concentration. That is, the drug 
delivery system should deliver drug at a rate dedicated by the needs of 
the body over a specified period of treatment. Oral route of drug 
administration is most appealing route for delivery of drugs for 
various dosage forms. The tablet is one of the most preferred dosage 
forms, because of its ease of administration, accurate dosing and 
stability as compared to oral liquid dosage forms.  
            Tablets may be defined as solid unit pharmaceutical dosage 
forms containing drug substance with or without suitable excipients 
and prepared by either compression or molding methods (Aulton M.et 
al., 2002). 
The first step in the development of dosage form is preformulation, 
which can be defined as investigation of physiochemical properties of 
drug substances alone and when combined with excipients. The main 
objective of preformulation studies, is to develop stable and 
bioavailable dosage form and study of factors affecting such as 
stability, bioavailability and to optimize so as to formulate the best 
dosage form. Here, optimization of formulation means finding the best 
possible composition (Ansel H.et al., 2004). Compressed tablets are 
formed by applying pressure, for which compression machines (tablet 
presses) are used and they are made from powdered crystalline or 
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granular material, alone or in combination with binder, disintegrants, 
release polymers, lubricants and diluents and in some cases with 
colorant. 
1.1 Tablets  
Tablets may be defined as the solid pharmaceutical dosage forms 
containing drug substances with or without suitable diluents and 
prepared either by compression or moulding methods. They have been 
in wide spread use since the latter part of the 19th century and their 
popularity continues. The term compressed tablet is believed to have 
been first used by “JOHN WYETH”. Tablets remain popular as a 
dosage form because of the advantages afforded both to the 
manufacturer and the patient (Banker GS.et al., 2002). 
1.1.1 Properties of tablets  
The attributes of an acceptable tablet are as follows: 
 The tablet must be sufficiently strong and resistant to shock, 
abrasion, should withstand handling during manufacturing, packing, 
shipping, and use. Hardness and friability tests measure this 
property. 
 Tablet must be uniform in weight and in drug content of the 
individual tablet. This is measured by the weight variation and 
content uniformity tests. 
 The drug content of the tablet must be bioavailable. This 
property is measured by the dissolution test. Accurate bioavailability 
can be obtained from the drug levels in the blood after its 
administration. 
 Tablets must be elegant in appearance, characteristic shape, 
color and other markings necessary to identify the product. 
 Tablets must retain all these functional attributes which include 
drug stability and efficacy (Herbert A.et al., 2003). 
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1.1.2 Advantages of Tablets 
 They are unit dosage forms, so they offer greater capabilities of 
all oral dosage forms for the greatest dose precision and the least 
content variability. 
 They are easy to administer. 
 Large scale manufacturing is feasible in comparison to other 
dosage forms. Therefore economy can be achieved. 
 Accuracy of dose is maintained since tablet is a solid unit 
dosage form. 
 Longer expiry period and minimum microbial spillage owing to 
lower moisture content. 
 As tablet is not a sterile dosage form, stringent environmental 
conditions are not required in the manufacturing department. 
 Ease of packaging (Blister or Strip) and ease of handling over 
liquid dosage forms. 
 In comparison to capsules, tablets are more tamper proof. 
 
  1.1.3 Disadvantages of tablets: 
 Some drugs resist compression into dense compacts, owing to 
their amorphous nature or flocculent, low density character. 
 Drugs with poor wetting, slow dissolution properties, 
intermediate to large dosages, and optimum absorption in the 
gastrointestinal tract or any combination of these features may be 
difficult or impossible to formulate and manufacture as a tablet that 
will still provide adequate bioavailability. 
 Bitter tasting drugs, drugs with objectionable odour or drugs 
that are sensitive to oxygen or atmospheric moisture may require 
encapsulation or a special type of coating which may increase the cost 
of finished product. 
 Some drugs may be unsuitable for administration by oral route. 
 Difficult to swallow for kids, terminally ill and geriatric patients. 
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1.2 Types of tablets 
Tablets are classified as follows: 
1.2.1 According to the drug release rate from the tablet. 
1.2.2 According to the method of manufacturing. 
1.2.3 According to the route of administration or function. 
1.2.1.2 According to the drug release rate from the tablet (USP 
classification) 
(a) Immediate release or conventional tablets: The tablet is 
intended to be released rapidly after administration or the tablet is 
dissolved and administered as a solution. It is the most common type 
and it includes. 
 Disintegrating tablet 
 Chewable tablet 
 Sublingual tablet 
 Buccal tablet 
 Effervescent tablet 
(b) Modified release tablets: They have release features based on 
time, course or location. They must be swallowed intact. 
 Delayed release tablets – Drug release is delayed due to 
physiological conditions. 
 Extended release tablet – Allows the reduction in dosing 
frequency. 
1.2.1.3 According to the method of manufacturing: 
(a) Compressed tablet: It is obtained by compressing uniform 
volume of particles using “Tablet compression machine”. It is used for 
large scale production. e.g. paracetamol tablet. 
(b) Moulded tablet: Moulding means shaping, hardening of 
semisolid mixture of drug and excipients. It is obtained by “tablet 
mould”. It is restricted to small dose tablet and small scale 
production. e.g. Nitro-glycerine Tablet (Herbert A.et al., 2003). 
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1.2.1.4 According to the route of administration: 
i) Tablets ingested orally: These tablets are to be swallowed intact 
with sufficient quantity of water. Exception is chewable tablet. Over  
99% of the tablets manufactured today are to be ingested orally. This 
shows that this class of formulation is most popular worldwide. 
a. Compressed tablets 
b. Multi compressed tablets  
c. Multi layered tablets 
d. Sustained action tablets 
e. Enteric coated tablets 
f. Sugar coated tablets 
g. Film coated tablets 
h. Chewable tablets  
i. Targeted tablets 
ii) Tablets used in oral cavity: The tablets under this group are 
aimed to release API    in oral cavity or to provide local action in this 
region. The tablets under this category avoids first-pass metabolism, 
decomposition in gastric environment, nauseatic sensations and gives 
rapid onset of action. The tablets formulated for this region are 
designed to fit in proper region of oral cavity. 
a) Buccal tablets 
b) Sublingual tablets 
c) Lozenge tablets and trouches 
d)  Dental cones 
iii) Tablets administered by other routes: These tablets are 
administered by other route other than oral cavity and so the drugs 
are avoided from passing through the gastro intestinal tract. These 
tablets may be inserted into other body cavities or directly placed 
below the skin to be absorbed into systemic circulation from the site 
of application. 
a)  Implants 
b)  Vaginal tablets 
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iv) Tablets used to prepare solutions: The tablets under this 
category are required to be dissolved first in water or other solvents 
before administration or application This solution may be for oral 
ingestion or parenterals application or for topical use depending on 
the type of medicament used. 
eg: Effervescent granules 
v) Molded tablets or tablet triturates: 
a)  Dispersing tablets 
b)  Hypodermic tablets 
 
1.3 Immediate release drug delivery system 
Immediate release drug delivery system is also conventional type of 
drug delivery system as it is defined as – Immediate release tablets are 
designed to disintegrate and release their medicaments with no 
special rate controlling features such as special coatings and other 
techniques (Syed azeem.et al., 2011). 
 
1.3.1 Advantages of immediate release drug delivery systems: 
 Release the drug immediately. 
 More flexibility for adjusting the dose. 
 It can be prepared with minimum dose of drug. 
 There is no dose dumping problem. 
 Immediate release drug delivery systems used in both initial 
stage and final stage of disease. 
 At the particular site of action the drug is released from the 
system. 
 
1.4 Tablet-manufacturing methods 
A). Direct compression 
B). Granulation 
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A) Direct compression 
 The term “direct compression” is defined as the process by 
which tablets are compressed directly from powder mixture of API and 
suitable excipients. No pretreatment of the powder blend by wet or dry 
granulation procedure is required. (G.S.Banker.et al., 2002).  
Manufacturing steps for direct compression 
Direct compression involves comparatively few steps: 
 Milling of drug and excipients 
 Mixing of drug and excipients 
 Tablet compression 
 
 B) Granulation 
Granulation may be defined as a size enlargement process 
which converts small particles into physically stronger and larger 
agglomerates. 
Granulation Techniques 
(1) Dry Granulation 
(2) Wet Granulation 
1.4.1 Dry granulation: 
When tablet ingredients are sensitive to moisture or are unable to 
withstand elevated temperature during drying and when the tablet 
ingredients have sufficient inherent binding or cohesive properties, 
slugging may be used to form granules. This method is referred to as 
dry granulation, pre compression or double compression. When 
slugging is used, large tablets are made as slugs because fine powders 
flow better into large cavities. These compressed slugs are 
comminuted through the desirable mesh screen either by hand or for 
large quantities through the Fitzpatrick or similar comminuting mills 
after this the granulation is blended gently with lubricants and then 
compressed to form tablets. The other method is to pre compress the 
powder with pressure rolls using a machine such as Chilsonator 
(Lieberman H.et al., 1986). 
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Steps in Dry Granulation: 
 Milling of drugs and excipients. 
 Mixing of milled powders. 
 Compression into large, hard tablets to make slugs. 
 Screening of slugs. 
 Mixing with lubricant and disintegrating agent. 
 Tablet compression. 
Two main Dry Granulation processes: 
 a) Slugging process: Granulation by slugging is the process of 
compressing dry powder of tablet formulation with tablet press having 
die cavity large enough in diameter to fill quickly. The accuracy or 
condition of slug is not too important. Only sufficient pressure to 
compact the powder into uniform slugs should be used. Once slugs 
are produced they are reduced to appropriate granule size for final 
compression by screening and milling. 
b) Roller compaction: The compaction of powder by means of 
pressure roll can also be accomplished by a machine called 
Chilsonator. Unlike tablet machine, the chilsonator   turns out a 
compacted mass in a steady continuous flow. The powder is fed down 
between the rollers from the hopper which contains a spiral auger to 
feed the powder into the compaction zone. Like slugs, the aggregates 
are screened or milled for production into granules. (Remington J. et 
al., 2005). 
 
 
1.4.2 Wet granulation: 
The most widely used process of agglomeration in pharmaceutical 
industry is wet granulation. Wet granulation process simply involves 
wet massing of the powder blend with a granulating liquid, wet sizing 
and drying the unique portions of wet granulation process involve the 
wet massing of powders, wet sizing or milling and drying. 
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Important steps involved in the Wet Granulation: 
 Mixing of the drug(s) and excipients. 
 Preparation of binder solution. 
 Mixing of binder solution with powder mixture to form wet 
mass. 
 Coarse screening of wet mass using a suitable sieve. 
 Drying of moist granules. 
 Screening of dry granules through a suitable sieve. 
 Mixing of screened granules with disintegrant, glidant, and 
lubricant (Ansel H.et al., 2004). 
1.5 Tablet compression 
After the preparation of granules (in case of wet granulation) or sized 
slugs (in case of dry granulation) or mixing of ingredients (in case of 
direct compression), they are compressed to get final product. The 
compression is done either by single punch machine (stamping press) 
or by multi station machine (rotary press). 
The tablet press is a high-speed mechanical device. It 'squeezes' the 
ingredients into the required tablet shape with extreme precision. It 
can make the tablet in many shapes, although they are usually round 
or oval. Also, it can press the name of the manufacturer or the 
product on the top of the tablet. Each tablet is made by pressing the 
granules inside a die, made up of hardened steel. The die is a disc 
shape with a hole cut through its centre. The powder is compressed in 
the centre of the die by two hardened steel punches that fit into the 
top and bottom of the die. 
The punches and dies are fixed to a turret that spins round. As it 
spins, the punches are driven together by two fixed cams - an upper 
cam and lower cam. The top of the upper punch (the punch head) sits 
on the upper cam edge .The bottom of the lower punch sits on the 
lower cam edge. The shapes of the two cams determine the sequence 
of movements of the two punches. This sequence is repeated over and 
over because the turret is spinning round. The force exerted on the 
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ingredients in the dies is very carefully controlled. This ensures that 
each tablet is perfectly formed. Because of the high speeds, they need 
very sophisticated lubrication systems. The lubricating oil is recycled 
and filtered to ensure a continuous supply (Ansel H.et al., 2004). 
 
Fig: 1&2 Rotary Punching Machine 
LIQUISOLID COMPACTS 
 
In recent years much attention has been focussed on the problem of 
drug bio-availability. The dissolution rate of a drug from its dosage 
form is now considered as an important parameter in the bio-
availability. Dissolution is the rate limiting step in the absorption of 
drugs from solid dosage forms, especially when the drug is poorly 
soluble. Among the various approaches to improve the dissolution of 
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the drugs, the preparation of solid dispersion has often proven to be 
very successful.  
Because of the limited aqueous solubility it exhibits poor dissolution 
characteristics and its oral absorption is dissolution rate limited.  
I) STUDIES ON SOLUBILITY IMPROVEMENT:  
The most important property of a dosage form is its ability to deliver 
the active ingredient to its site of action at a rate and amount sufficient 
to elicit the desired pharmacological response. If the drug is 
administered by an extra vascular route and acts systemically, its 
potency will be directly related to the amount of drug the dosage form 
delivers into the blood. Also, if the pharmacological effects of the drug 
are directly and instantaneously related to the plasma concentration, 
the rate of absorption will be important because the rate will influence 
the height of plasma concentration peak and peak time. Thus, the 
bioavailability of a drug product is defined in terms of the amount of 
the active drug delivered to the blood and the rate at which it is 
delivered. The successful transportation of a drug from oral solid 
dosage form into the general circulation can be considered as a four 
step process.  
1. The delivery of drug to the absorption site.  
2. Getting the drug into solution.  
3. Movement of the drug through the membrane of the gastrointestinal 
tract.  
4. The movement of the active ingredient from the site of absorption 
into the general circulation.  
The order of the first two steps is not absolute i.e., the drug may 
dissolve either before or after reaching the site of absorption, but it is 
imperative that the drug be in solution before it is absorbed.  
The slowest of the process determines the rate of availability of the 
drug from the dosage form. The rate and extent of absorption will be 
influenced by many factors in all the four of these steps. These factors 
Chapter I                                                                                           INTRODUCTION 
Department Of Pharmaceutics,rvs college of pharmaceutical sciences Page 12 
  
related to the physio-chemical properties  of the drug, and the design 
and production of the dosage form are called pharmaceutical variables 
and those factors arising from the anatomical and physiological  
characteristics of the patient are called patient variables. 
The factors related to the dosage form that can produce profound 
differences in the drug bioavailability include, formulation and 
manufacturing variables, such as chemical form and solubility of the 
drug, the type and quantity of the excipients used and the compaction 
pressure. Among the patient related factors that control bioavailability 
include the time of drug administration relative to meals, Co-
administration of other drugs which may influence absorption and the 
compliance of the patient with the instructions of the physician, 
pharmacist or nurse. Patient related factors which normally cannot be 
controlled but for which some all owance or adjustment can be made 
include age, disease state, abnormal genital characteristics and/ or 
gastrointestinal physiology.  
 
II) DISSOLUTION RATE LIMITED ABSORPTION: 
   The poor dissolution characteristics of relatively insoluble drugs 
have long been problem to the pharmaceutical industry. When an 
insoluble or sparingly soluble drug is administered orally, the rate 
and extent of absorption are controlled by the dissolution rate in 
the gastrointestinal fluids.  
The process of dissolution is primarily dependent on 
pharmaceutical variables with the possible exception of ph 
dependency which may be patient variable.  
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A quantitative description of dissolution rate is given by the   
Noyes-Whitney equation based on diffusion layer model.  
    dc              DS (c s -c) 
      _ __           =   ________  
      dt                            h 
Where, 
        dc / dt is the rate of diffusion,  
        S is the surface area,   
        D is the diffusion coefficient,  
        h is the thickness of the diffusion layer, 
        Cs is the saturation solubility and 
        C is the concentration of the drug in the solvent at time’s’. 
In dissolution rate limited absorption ‘C’ is negligible when 
compared to   ‘Cs’. Under these conditions ‘D’ and ‘h’ remain 
constant and cannot be altered to any degree by the product 
formulation. Hence,  
 
dc / dt = K.S.CS 
Thus, the dissolution rate of a poorly soluble drug can be increased 
by increasing either solubility or surface area or both.  
 
Methods Used For Increasing the Dissolution Rate of Poorly 
Soluble Drugs:  
Noyes–Whitney equation states that the variables to be controlled 
by formulation are simply the surface area and solubility.  
1. Controlling the solubility of a weak acid or base by buffering the 
entire dissolution medium, the microenvironment of the diffusion layer 
surrounding a particle through the use of buffers and salts.  
2. Controlling the solubility of the drug through the choice of the 
physical state such as crystal forms, its hydrates, its amorphous form 
and so on.  
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3. Controlling the surface area of the drug through control of the 
particle size.  
A solid dispersion is defined as “a dispersion of one or more active 
ingredients in an inert carrier or matrix of solid state prepared by the 
melting (fusion), solvent or melting solvent method”.  
III)  METHOD OF PREPARATION: 
1. Melting Method: 
In the melting Method, a physical mixture of a drug and a water 
soluble carrier was heated directly until it melted mixture was then 
cooled and solidified rapidly in an ice bath under vigorous stirring. The 
final solid mass was then crushed, pulverized and sieved. To facilitate 
faster solidification, the homogenous melt was poured in the form of a 
thin layer on to a ferriteplateora stainless steel plate and cooled by 
following air or water in the opposite side of the plate. The solidified 
masses of some systems like drug poly ethylene glycol polymer were 
often found to require storage of one or more days in desiccators at 
ambient temperatures for hardening and ease of powdering. 
The main advantages of this method are its simplicity and economy. It 
is technically less difficult method of preparing dispersions provided 
drug and carrier are miscible in the molten state. There is no use of 
toxic solvents. A modification of the melt process involves spray 
congealing from a modified spray drier on to cold metal surfaces and 
has been used for dispersions. 
The disadvantages are that many substances, either drugs of carriers 
may decompose or evaporate during fusion processes at high 
temperatures. For example some carriers are quite volatile and may 
partially decompose by dehydration near its melting point that 
immiscibility and instability may occur during fusion. The other 
potential problem of carriers such as thermal degradation, sublimation 
and polymorphic transformation since Meta stable modification of the 
drug maybe formed which convert to more stable forms during 
storage..  
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2. Solvent method:  
In the solvent method, solid dispersions are prepared by dissolving of 
two solid components in a common solvent, followed by evaporation of 
the solvent .More commonly; the solvent is removed by evaporation 
under reduced pressure at varying   temperatures. The process uses 
organic solvent as the agent to intimately mix the drug and carrier to 
prepare solid dispersion. The choice of solvent and its removal rate are 
critical to the quality of the dispersion. Since the chosen carriers are 
generally hydrophilic and the drugs are hydrophobic, the selection of a 
common solvent is difficult and its complete removal necessitated by 
its toxic nature, is imperative careful control of the temperature and 
rate of evaporation of solvent is essential in controlling the particle size 
of the drug, and although low temperatures and in vacuum 
evaporation may be used for solvent removal, instabilities cannot 
always be avoided.  
The main advantage of the solvent method is that thermal 
decomposition of drugs or carriers can be prevented because of the low 
temperatures required for the evaporation of organic solvents. 
Insolvent method high melting carriers can be used.  
However, some disadvantages associated with this methods are the 
higher cost of preparation, the difficulty incompletely removing the 
solvent, the possible adverse effects of the supposedly negligible 
amount of the solvent on the chemical stability of the drug, the 
selection of common volatile solvent and the difficulty of reproducing 
crystal forms.  
  The BCS class II drugs for which the dissolution profile must be 
clearly defined and reproducible shows high absorption number (an) 
and low dissolution  number (dn).Drugs in this class are expected to 
have a variable dissolution profile due to the formulation and in vivo 
variables that, in turn, affect the absorption. The poor dissolution rate 
of such water insoluble drug is a major impediment to the 
development of pharmaceutical dosage forms. The oral absorption of 
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drugs is most often controlled by dissolution in the gastrointestinal 
tract.   Different methods are employed to improve the dissolution 
characteristics of poorly water soluble drugs, like solubilisation, pH 
adjustment, co-solvents, micro emulsion, self emulsification, 
polymeric modification, drug complication, particle size reduction, use 
of a surfactants a solubilising agent, the pro-drug approach, and solid 
solutions. Amongst these the most promising method for promoting 
dissolution is the use of the liquisolid (LS) system. Liquisolid systems 
are acceptably flow inland compressible powdered forms of liquid 
medications. 
The term ‘liquid medication’ involves oily liquid drugs and solutions or 
suspensions of water insoluble solid drugs carried in suitable non-
volatile solvent systems termed liquid vehicles. Employing this 
Liquisolid technique, a liquid medication maybe converted into a dry 
looking,  non-adherent, free flowing and readily compressible powder 
by a simple blending with selected  powder excipients referred to as 
carrier and coating materials. Various grades of cellulose, starch and 
lactose maybe used as the carriers, where as very fine particle size 
silica powders may be used as the coating (or covering) materials .In 
fundamental studies made by Spire as etal., flow and compression 
issues have been addressed with the use of the new formulation 
mathematical model of liquisolid systems, which is based on the flow 
able (Ф-value) and compressible (Ψ-number) liquid retention potentials 
of the constituent powders. The good flow and compression properties 
of the liquisolid system are encouraged by the large surface area and 
fine particle size. Hence, liquisolid compacts containing water-insoluble 
drugs are expected to display enhanced dissolution characteristics 
and, consequently, improved oral bioavailability. 
 
Therapeutic effectiveness of a drug depends upon the bioavailability 
which is dependent on the solubility of drug molecules. Solubility is 
one of the important parameter to achieve desired concentration of 
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drug in systemic circulation for pharmacological response to be shown 
.A number of new chemical entities do not reach the public merely 
because of their poor oral bioavailability due to in adequate 
dissolution. For drugs belonging to Biopharmaceutical Classification 
System (BCS) class II (poor water solubility and high permeability) 
dissolution rate is often the rate determining step in the drug 
absorption. To increase dissolution rates of such drugs, various 
methods have been described. These include the use of micronization, 
modification of the crystal habit, solid dispersions, inclusion complexes 
using cyclodextrin, Solubilisation by surfactants, Microwave induced 
dissolution rate improvement etc. Among them liquisolid compacts is 
one of the most promising and new technique which promotes the 
dissolution rate of water insoluble drugs. 
 
LIQUID SOLID COMPACTS 
Liquisolid Compacts - A Novel Approach 
The new Liquisolid technique may be applied to formulate liquid 
medications (i.e., oily liquid drugs and solutions, suspensions or 
emulsions of water insoluble solid drugs carried in non-volatile 
liquid vehicles) into powders suitable for tableting or encapsulation. 
Simple blending of such liquid medications with calculated 
quantities of a powder substrate consisting of certain excipients 
referred to as the carrier and coating powder materials, can yield 
dry looking, non adherent, free flowing, and readily compressible 
powders.  
Type of Liquisolid compacts based on the liquid medication:- 
1. Powdered drug solutions  
2. Powdered drug suspensions  
3. Powdered drug emulsions 
4. Powdered liquid drug 
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Concept 
When the drug dissolved in the liquid vehicle is incorporated into a 
carrier material which has a porous surface and closely matted 
fibres in its interior as cellulose, both absorption and adsorption 
take place; i.e., the liquid initially absorbed in the interior of the 
particles is captured by its internal structure and, after the 
saturation of this process, adsorption of the liquid on to the 
internal and external surfaces of the porous carrier particles occur. 
Then, the coating material having high adsorptive properties and 
large specific surface area gives the liquisolid system the desirable 
flow characteristics.  
In liquisolid systems the drug is already in solution in liquid vehicle, 
while at the same time, it is carried by the powder particles 
(microcrystalline cellulose and silica). Thus, due to significantly 
increased wetting properties and surface area of drug available for 
dissolution, liquisolid compacts of water-insoluble substances may be 
expected to display enhanced drug release characteristics and 
consequently, improved Oral bioavailability. Since dissolution of a 
non polar drug is often the rate limiting step in gastro intestinal 
absorption, better bioavailability of an orally administered water-
insoluble drug is achieved when the drug is already in solution, 
thereby displaying enhanced dissolution rates. That is why soft 
gelatin elastic capsules containing solutions of such medications 
demonstrate higher bioavailability when compared to conventional 
Oral solid dosage forms. A similar principle underlies the 
mechanism of drug delivery from liquisolid compacts and is chiefly 
responsible for the improved dissolution profiles exhibited by these 
preparations. The wettability of the compacts by the dissolution 
media is one of the proposed mechanisms for explaining the 
enhanced dissolution rate from the liquisolid compacts. Non volatile 
solvent present in the liquisolid system facilitates wetting of the drug 
particles by decreasing interfacial tension between dissolution 
Chapter I                                                                                           INTRODUCTION 
Department Of Pharmaceutics,rvs college of pharmaceutical sciences Page 19 
  
medium and tablet surface.  
Mechanism of Liquisolid Compacts 
Liquisolid system is a novel concept of drug delivery via oral route. 
This technique is applied to water insoluble drugs and lipophilic 
drugs to sustain their release. Formulation and manufacture of the 
liquisolid tablet is quite simple method according to new 
mathematical model described by Spires etal. The liquisolid tablet 
preparation method involves, first a mathematically calculated 
amount of pure drug weighed and dissolved in the suitable amount 
of solvent in a molecularly dispersed state. For attaining good flow 
properties trial and error methods were used i.e. changing the 
carrier: coating material ratio from 50:1 to 5:1 ratios according to 
new mathematical model expressions proposed by Liao. This liquid 
medication is poured on the suitable amount of carrier material. 
The liquid medication is absorbed in to the carrier    material 
internally and externally and then suitable disintegrant was added 
to this material. Finally, coating material was added for dry looking 
adherent to the carrier material for achieving good compression 
properties. As the drug is in the form of liquid medication it is 
either solubilised or molecularly dispersed state. Due to increased 
wetting and surface area for dissolution, liquisolid tablet of water 
insoluble drugs shows improved dissolution properties and in turn 
increased bioavailability. 
Liquid medication is incorporated into carrier medication which 
has a porous surface and closely matted fibres’ in its interior as 
cellulose. Both absorption and adsorption take place, i.e. the liquid 
absorbed into the interior of the particles is captured by its 
internal structure and after saturation of this process, adsorption 
of the liquid onto the internal and external surface of the porous 
carrier particles occurs. Excipients possessing fine and highly 
adsorptive particles such as various types of amorphous silicon 
dioxide (silica) are most suitable for this step. Before compression 
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or encapsulation, various ingredients such as lubricants, 
disintegrates or Polymers, and binders, maybe mixed with the 
finished liquisolid systems to produce liquisolid compacts in the 
dosage form of tablets or capsules. 
 
 Fig 3: Mechanism of Liquisolid Compacts 
Steps involved in the preparation of Liquisolid compacts 
 
Designing of Liquisolid Systems 
Before designing the liquisolid, the Pre formulation studies should be 
performed first, these include:-  
1. Determination of drug in different non-volatile solvents  
2. Determination of angle of slide 
3. Calculation of liquid load factor (Lf)  
4. Determination of flowable liquid retention potential (Φ value) 
5. Liquid solid compressibility test (LSC) 
The flowability and compressibility of liquisolid compacts are 
addressed concurrently in the new formulation mathematical model of 
liquisolid systems, which was used to calculate the appropriate 
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quantities of the carrier and coating materials required to produce 
acceptably flowing and compressible powders based on new 
fundamental powder properties called the flow able liquid retention 
potential (Φ- value) and compressible liquid retention potential (Ψ-
number) of the constituent powders. According to the new theories, 
the carrier and coating powder material can retain only certain 
amounts of liquid while maintaining acceptable flow and compression 
properties. Depending on the excipients ratio (R) or the carrier: 
coating ratio of the powder system used where, 
R = Q/q E q….. (1) 
As represents the ratio between the weights of carrier (Q) and 
coating (q) materials present in the formulation. 
Determination of Drug in Different Non Volatile Solvents: 
These are carried by preparing saturated solutions of drug in non-
volatile solvents, and analyzing them spectrophotometrically. 
Saturated solutions are prepared by adding excess of drug to 
vehicles and shaking them on shaker for specific time period under 
steady vibration. After this, the solutions are filtered and analyzed 
spectrophotometrically. 
 
Determination of Angle of Slide: 
The required amount of carrier is weighed and placed at one of a 
metal plate with a polished surface and it is gradually raised till 
the plate becomes angular to the horizontal at which powder is 
about to slide. 
It was used to measure the flow properties of powders. The angle of 
33° is optimum for flow of powders.  
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Calculation of Liquid Load Factor (Lf):  
It is defined as the ratio of weight of liquid medication (w) to weight 
of carrier material (Q). 
Different concentrations of non-volatile solvents are taken and the 
drug is dissolved and the carrier coating material is added and 
blended.  
Lf = W/Q          e q……. (2) 
W = weight of liquid medication 
Q = weight of carrier material 
 
 
Determination of Flowable Liquid Retention Potential (Φ): 
It is defined as the maximum weight of liquid that can be retained per 
unit powder material in order to produce an acceptably flowing 
liquid/powder admixture. This value of powders maybe determined 
using a new procedure, the liquisolid flow ability (LSF) test. The Ø 
value was used to calculate excipients quantities. Equation for this is 
as follows: 
Lf   =   Ø + Ø (1/R) eq….. (3) 
Where Ø and Ø are the constant Ø values of carrier and coating 
materials, respectively. Lf was calculated from the linear 
relationship of Lf   vs 1/R. 
Lf   =    (1/R) eq…… (4) 
Next according to the used liquid vehicle concentration, different 
weights of the liquid drug solution (W) will be used. By calculating 
Lf and W, we can calculate the amount of Q and q required for 
liquisolid systems. 
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Liquisolid Compressibility Test (LSC): 
It was developed to determine Ψ values and involves steps such as 
preparing carrier coating material admixture systems, preparing 
several uniform liquid/powder admixtures to tablets, determining 
average hardness, measuring of average liquid content  
              
SIGNIFICANCE OF LIQUISOLID COMPACTS  
1) Huge number of Bio-Pharmaceutical classification class II drugs with 
high permeability, slightly or very slightly water soluble and practically 
insoluble liquids and solid drugs can be formulated into liquisolid systems. 
2) Improvement of bioavailability of an orally administered water insoluble 
drugs is achieved. 
3) This principle governs or administers the mechanism of drug delivery 
from liquisolid systems of powdered drug solutions and it is mainly 
responsible for the improved dissolution profiles exhibited by this 
preparations. 
4) In this technique, production cost is low compared to soft gelatin 
capsules. 
5) Drug is formulated in a tablet form or encapsulated dosage form and is 
held in solubilised liquid state, which confers developed or improved drug 
wetting properties thereby improving drug dissolution profiles. 
6) Greater drug surface area is exposed to the dissolution medium. 
7) This liquisolid system is specifically for powdered liquid medications. 
8) These liquisolid systems formulate into immediate release or 
sustained release   dosage forms. 
9) Optimized sustained release, liquisolid tablets or capsules of water 
insoluble drugs demonstrate constant dissolution rates. 
10) It is used in controlled drug delivery systems. 
11) Drug can be molecularly dispersed in the formulations. 
12) Drug release can be modified using suitable formulation 
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ingredients. 
13) Capability of industrial production is also possible. 
14) Enhanced bioavailability can be obtained as compared to 
conventional tablets. 
15) Differentiate the dosage form by admixture of colour into liquid 
vehicle. 
16) To minimize excipients in formulation compare with other 
formulations like solid dispersions. 
17) Omit the process approaches like nanonisation, micronization 
techniques. 
Applications of Liquisolid Systems 
 Solubility and dissolution enhancement. 
 Used efficiently for water insoluble solid drugs or liquidlipophilic   
drugs. 
 Rapid release rates. 
 Designed for controlled release tablets. 
 Designed for sustained release of water soluble drugs such 
as Propronolol hydrochloride. 
 Application in probiotics. 
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AIM AND OBJECTIVE OF THE WORK  
        The aim and objective of the present study is to develop a 
pharmaceutically stable, cost effective and quality improved robust 
formulation of Loperamide tablets using liquisolid technique.   
Oral route still remains the convenient route of drug administration in 
many diseases. That the major problem in oral drug formulations is 
low and erratic bioavailability, which mainly results from poor 
aqueous solubility of certain drugs. Incase of poorly water soluble 
drugs, dissolution is the rate limiting step in the process of drug 
absorption. So, bioavailability problems are prevalent with extremely 
hydrophobic drugs (aqueous solubility <3.4 mg /ml at 37 ͦC). The 
enhancement of oral bioavailability of poorly water soluble drugs like 
LOPERAMIDE could be improved by enhancing aqueous solubility. 
Among numerous ways of enhancing drug dissolution, liquisolid 
compacts are the promising techniques to enhance the dissolution 
poorly water soluble drugs. 
        To achieve this goal various prototype formulation trials will be 
taken and evaluated with respect to the various quality control 
parameters such as dissolution, assay. The formula will be finalized 
by dissolution profile. The objective includes providing a robust 
formulation for the production of the dosage form for which the 
influence of various factors like concentration and nature of non 
volatile solvents along with type of disintegrates used on 
disintegration time and dissolution parameters are to be studied and 
also analyzed. 
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PLAN OF WORK 
       With the above mentioned aims and objectives, the work is 
planned as follows: 
Survey of literature on Loperamide liquisolid compacts. 
1. Solubility studies. 
2. Pre formulation studies:   
Blend:    Bulk Density, Tapped Density, Angle of repose, Carrs’ Index. 
3. Formulation of the dosage form. 
4. Selection of method of preparation of dosage form. 
5. Evaluation of dosage form for 
i. Hardness 
ii. Friability 
iii. Disintegration 
iv. Weight variation 
v. Dissolution 
vi. Drug content  
vii. Compatibility studies 
viii. Powder X-Ray Diffraction 
ix. Stability studies. 
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3. LITERATURE REVIEW 
Sanjeev Raghavendra Gubbi 1 Purpose: The solubility and dissolution 
properties of any drug are vital determinants of its oral bioavailability. 
The dissolution rate of poorly soluble, highly permeable (BCS-II) drugs, 
such as atorvastatin calcium, can be improved by application of the 
liquisolid (LS) technique. Methods: Different liquisolid compacts were 
prepared using a mathematical model for calculating required quantities 
of powder and liquid ingredients to produce an acceptably flowable and 
compressible admixture. Avicel PH 102, Aerosil 200 and Explotab were 
employed as carrier, coating material and disintegrant, respectively. The 
prepared liquisolid systems were evaluated for their    micromeritic 
properties and possible drug-excipient interactions by Infrared spectra 
(IR) analysis, differential scanning calorimetry (DSC) and X- ray powder 
diffraction (XRPD). Liquisolid compacts were prepared and evaluated for 
their tabletting  properties. 
Results: The liquisolid system showed acceptable micromeritic 
properties. The IR and DSC studies ruled out any significant interaction 
between the drug and excipients. The XRPD analysis confirmed 
formation of a solid solution inside the compact matrix. The tabletting 
properties of the liquisolid compacts were within the acceptable limits. 
The release rates of liquisolid compacts were markedly higher compared 
with directly compressed tablets, due to increasing wetting properties 
and surface area of the drug. From the obtained pharmacokinetic 
parameters, such as the AUC, Tmax and Cmax, the liquisolid compacts 
demonstrated better bioavailability compared with their conventional 
formulation.  
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Tejaswi Annapureddy 2 It is well established that the active ingredient 
in a solid dosage form must undergo dissolution before it is available for 
absorption from the GIT. About 40 % of the newly discovered drugs fall 
into poorly water soluble or water insoluble categories. The aqueous 
solubility for poorly water soluble drugs is usually less than 100 µg/ml. 
Liquisolid compact system is a novel concept of drug delivery that can 
change the dissolution rate of water insoluble drugs. Formulation and 
manufacture of the Liquisolid compacts is quite simple method according 
to new mathematical model described by Spire as et al. The technique is 
based up on dissolving the insoluble drug in the non-volatile solvent and 
admixture of drug loaded solutions with appropriate carrier and coating 
materials to convert into acceptably flowing and compressible powders. 
In this case, even though the drug is in a solid dosage form, it is held 
within the powder substrate in solution, or in a solubilised, almost 
molecularly dispersed state, which contributes to the enhanced drug 
dissolution properties. Liquisolid system is characterized by flow 
behaviour, saturation solubility, drug content, Fourier transform infra 
red spectroscopy, in-vitro release, release kinetics and stability studies. 
Therefore, the optimum liquid load factor (Lf) required to obtain 
acceptably flowing and compressible liquisolid systems are equal to 
either ΦLforΨLf,3 whichever represents the lower value. As soon as the 
optimum liquid load factor is determined, the appropriate quantities of 
carrier (Qo) and coating (qo) material required to convert a given amount 
of liquid formulation (W) into an acceptable. Several mechanisms of 
enhanced drug release have been postulated for liqui-solid systems. The 
three main suggested mechanisms include an increased surface area of 
drug available for release, an increased aqueous solubility of the drug, 
and an improved wet ability of the drug particles. Formation of a complex 
between the drug and excipients or any changes in crystalline of the drug 
could be ruled out using DSC and XRPD measurements. 
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Vijasya ranga vital 4 Liquisolid techniques is used in delivery of 
lipophilic and poorly water soluble drugs through oral route. It involves 
dissolving water insoluble drugs in nonvolatile solvents and converting 
into acceptably flowing and compressible powders. The objective of the 
present work was to enhance the dissolution rate of ketoprofen using 
microcrystalline cellulose as carrier, Aerosil 200 as coating material, and 
polyethylene glycol as nonvolatile water miscible liquid vehicle. Materials 
and Methods: The drug concentration was kept constant in all 
formulations at 40% w/w. Optimization was carried out using Box-
Behnken design by selecting liquid load factor, amount of coating 
material, and amount of magnesium oxide as independent variables; 
cumulative percentage drug release and angle of repose were considered 
as dependent variables. Results: The Fourier transforms infrared (FTIR) 
and differential scanning calorimetry (DSC) studies revealed that there 
was no possible interaction between drug and tablet excipients. Prepared 
ketoprofen liquisolid tablets were evaluated for hardness, weight 
variation, friability, in-vitro disintegration time, drug content uniformity, 
and in-vitro dissolution studies. The optimized formulation yielded the 
response values, which were very close to the predicted values. The 
accelerated stability studies conducted showed that liquisolid tablets 
were not affected by ageing and there were no appreciable changes in the 
drug content. 
Abdul jabba 5 Objective: The purpose of the present research was to 
investigate the in vitro dissolution properties of poorly water soluble 
piroxicam by utilizing liquisolid technique. Different liquisolid (LS) 
compacts were prepared using a mathematical model to calculate the 
required quantities of powder and liquid ingredients to produce 
acceptably flowable and compressible admixture. Methods: Avicel PH 
102, Aerosil 200 and cros carmellose sodium were employed as carrier, 
coating material and disintegrant respectively for preparing LS compacts. 
LS compacts were prepared and evaluated for their tabletting properties. 
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Fourier transform infrared (FTIR) analysis, differential scanning 
calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. 
Results: The tabletting properties of the liquisolid compacts were within 
the acceptable limits and drug release rates of all prepared LS compacts 
were distinctly higher as compared to directly compressed tablets, and 
marketed capsules. Both DSC and XRPD suggested loss of piroxicam 
crystalline upon liquisolid preparation indicating that even though the 
drug existed in a solid dosage form, it is held within the powder 
substrate in a solubilized, almost molecularly dispersed state, which 
contributed to the enhanced drug dissolution properties. The FTIR 
spectra showed disappearance of the characteristic absorption band of 
piroxicam (3338.78 cm-1) in liquisolid formulations which might be 
attributed to the formation of hydrogen bonding between the drug and 
liquid vehicle; this resulted in drug dissolution enhancement. 
Conclusion: From this study it concludes that the LS technique is an 
effective approach to enhance the dissolution rate of piroxicam. 
V. J. Kapure 6In present investigation liquisolid compact technique is 
investigated as a tool for enhanced dissolution of poorly water-soluble 
drug Rosuvastatin calcium (RVT). The model drug RVT, a HMG-Co A 
reductase inhibitor was formulated in form of directly compressed tablets 
and liquisolid compacts; and studied for in-vitro release characteristics 
at different dissolution conditions. In this technique, liquid medications 
of water insoluble drugs in non-volatile liquid vehicles can be converted 
into acceptably flowing and compressible powders. Formulated systems 
were assessed for Precompression parameters like flow properties of 
liquisolid system, Fourier transform infra red spectra (FTIR) analysis, X-
ray powder diffraction (XRPD), differential scanning calorimetry (DSC), 
and post compression parameters like content uniformity, weight 
variation, hardness and friability, disintegration test, wetting time, in 
vitro dissolution studies, effect of dissolution volume on drug release 
rate, and estimation of fraction of molecularly dispersed drug in liquid 
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medication. As liquisolid compacts demonstrated significantly higher 
drug release rates, we lead to conclusion that it could be a promising 
strategy in improving the dissolution of poor water soluble drugs and 
formulating immediate release solid dosage forms. 
Srinivas Vaskula 7 The present study enlightens to enhance the 
dissolution rate, absorption efficiency and bioavailability of Nimesulide, a 
poorly soluble-highly permeable drug by preparing liquisolid compacts. 
Nimesulide liquisolid tablets were prepared by using polyethylene glycol-
400 as a non-volatile liquid vehicle, microcrystalline cellulose, hydroxyl 
propyl methylcellulose-E15, starch were used as carrier materials and 
silica gel as coating material in different ratios. They were characterized 
for different physical parameters to comply with pharmacopoeial limits. 
In vitro dissolution profiles of the liquisolid formulations were studied 
and compared with conventional formulation in pH 7.4 phosphate buffer 
and it was found that liquisolid tablets formulated with microcrystalline 
cellulose showed significant higher drug release rates than conventional 
tablets due to increase in wetting properties. DSC study showed that 
there is no interaction between the drug and excipients. In conclusion, 
development of nimesulide liquisolid tablets is a good approach to 
enhance the dissolution rate. 
V.N.L. Sirisha8 At present 40% of the drugs in the development 
pipelines, and approximately 60% of the drugs coming directly from 
synthesis are poorly soluble. The limited solubility of drugs is a 
challenging issue for industry, during the development of the ideal solid 
dosage form unit. Liqui-solid compacts technique is a new and promising 
approach to overcome this consequence and that can change the 
dissolution rate of water insoluble drugs and increase the bioavailability 
of the drugs. According to the new formulation method of liqui-solid 
compacts, liquid medications such as solutions or suspensions of water 
insoluble drugs in suitable non-volatile liquid vehicles can be converted 
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into acceptably flowing and compressible powders by blending with 
selected powder excipients. It has been speculated that such systems 
exhibit enhanced release profiles. In this case, even though the drug is in 
a solid dosage form, it is held within the powder substratin solution or, 
in a solubilised, almost molecularly dispersed state, which contributes to 
the enhanced drug dissolution properties 
Vijay kumar Nagaband 9 At present 40% of the drugs in the 
development pipelines, and approximately 60 % of the drugs coming 
directly from synthesis are poorly soluble. The limited solubility of drugs 
is a challenging issue for industry, during the development of the ideal 
solid dosage form unit. Liquisolid technique is a novel and promising 
approach to overcome this consequence. The technique is based upon 
the dissolving the insoluble drug in the non volatile solvent and 
admixture of drug loaded solutions with appropriate carrier and coating 
materials to convert into acceptably flowing and compressible powders. 
The selection of non toxic hydrophilic solvent, carrier, coating materials 
and its ratios are independent of the individual chemical moieties. The 
increased bioavailability is due to either increased surface area of drug 
available for release, an increased aqueous solubility of the drug, or 
improved Wettability of the drug particles. 
Izhar Ahmed Syed 10 The “Liquisolid” technique is a novel and capable 
addition towards such an aims for solubility enhancement and 
dissolution improvement, thereby it increases the bioavailability. It 
contains liquid medications in powdered form. This technique is an 
efficient method for formulating water insoluble and water soluble drugs. 
This technique is based upon the admixture of drug loaded solutions 
with appropriate carrier and coating materials. The use of non-volatile 
solvent causes improved wet ability and ensures molecular dispersion of 
drug in the formulation and leads to enhance solubility. By using 
hydrophobic carriers (non-volatile solvents) one can modify release 
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(sustained release) of drugs by this technique. Liquisolid system is 
characterized by flow behaviour, wettability, powder bed hydrophilicity, 
saturation solubility, drug content, differential scanning calorimetry, 
Fourier transform infra red spectroscopy, powder X-ray diffraction, 
scanning electron microscopy, in-vitro release and in-vivo evaluation. By 
using this technique, solubility and dissolution rate can be improved, 
sustained drug delivery systems be developed for the water soluble 
drugs. 
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DRUG PROFILE 
LOPERAMIDE:  
Formula :  C29H33Cl N2O2 
Fig.4: Structure of Loperamide  
 
IUPAC NAME:  4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-N, N-
dimethyl-2,2-diphenylbutanamide 
Routes :                              oral, insufflations 
Pharmacokinetic data: 
Bioavailability                  0.3% 
Protein binding                 97% 
Metabolism                       Hepatic (extensive) 
Half-life                            7-14 hours 
Excretion                          Faeces (30-40%), urine (1%) 
 
LOPERAMIDE HYDROCHLORIDE: 
 
Pharmacologic class:  Piperidine derivative 
Therapeutic class:       Anti diarrheal 
Molecular weight:         477.038 g/mol  
Melting point:                223-2250 C 
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Actions 
 Slows intestinal motility and affects water and electrolyte movement 
through the bowel.Inhibits peristaltic activity by a direct effect on 
circular and longitudinal muscles of the intestinal wall. 
 Prolongs the transit time of intestinal contents; reduces fecal volume, 
increases fecal viscosity and bulk density, diminishes loss of fluid and 
electrolytes. 
 Inhibits peristalsis of intestinal wall musculature and intestinal cont
ents. Also reduces fecal volume, increases fecal bulk, andminimizes 
fluid and electrolyte loss. 
Medical uses: 
Loperamide is effective for the treatment of a number of types 
of diarrhea. 
  This includes control of acute nonspecific diarrhea, mild traveller’s 
diarrhea, irritable bowel syndrome, chronic diarrhea due to bowel 
resection, and chronic diarrhea secondary to inflammatory bowel 
disease.   
Mechanism of action: 
 Loperamide is an opioid -receptor agonist and acts on the μ-opioid 
receptors in the myenteric plexus of the large intestine; by itself it does 
not affect the central nervous system. It works similarly to morphine, by 
decreasing the activity of the myenteric plexus, which in turn decreases 
the tone of the longitudinal and circular smooth muscles of the intestinal 
wall. This increases the amount of time substances stay in the intestine, 
allowing for more water to be absorbed out of the fecal matter. 
Loperamide also decreases colonic mass movements and suppresses 
the gastrocolic reflex. 
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Adverse effects: 
    Adverse drug reactions (ADRs) most commonly associated with 
loperamide are constipation , dizziness, nausea , and abdominal cramps  
Sideeffects: paralyticileus, angioedema,anaphylaxis/allergic 
reactions, toxic epidermal, necrolysis, Stevens-Johnson syndrome, 
erythema multiforme, urinary retention, and heat stroke. The most 
frequent symptoms of loperamide overdose are drowsiness, vomiting and 
abdominal pain or burning. 
Drug interactions: 
    Loperamide is a substrate of P-Glycoprotein, therefore the 
concentration of Loperamide will increase when given with a  P-
Glycoprotein inhibitor. Loperamide is also capable of decreasing the 
concentration of other P-Glycoprotein substrates. As an example, 
when saquinavir concentrations can decrease by half when given with 
loperamide.  
    Loperamide is an anti-diarrheal agent which decreases intestinal 
movement. As such, when combined with other anti motility drugs, there 
is an increased risk of constipation. These drugs include, but are not 
limited to opiates, antihistamines, antipsychotics, and anticholinergics.  
Contraindications: 
• Hypersensitivity . 
• Abdominal pain of unknown cause (especially with fever).  
• Acute diarrhea caused by enteroinvasive Escherichia coli, Salmonella,   
or Shigella. 
• Acute ulcerative colitis. 
• Bloody diarrhea with temperature above 38.3º C (101º F) (with OTC pro
duct).  
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• Pseudomembranous colitis associated with broad-spectrum anti-
infectives. 
• Children younger than age 6. 
Warnings/Precautions: 
Warnings: Do not use in patients with acute dysentery, characterized by 
high fever or blood in stools. 
Fluid and Electrolyte Replacement Therapy 
Fluid and electrolyte depletion may occur in patients with diarrhea; in 
such cases, administration of appropriate fluid and electrolytes is 
important. Use of loperamide does not preclude administration of 
appropriate fluid and electrolyte therapy. 
Infectious Diarrhea and Pseudomembranous Colitis 
Antiperistaltic agents may prolong and/or worsen diarrhea resulting 
from some infections (e.g., those caused by Shigella, Salmonella, 
toxigenic Escherichia coli) and from pseudomembranous colitis 
associated with broad spectrum antibiotics; do not use in these 
conditions. 
Toxic Megacolon 
Toxic megacolon reported with agents that inhibit intestinal motility or 
prolong intestinal transit time in some patients with acute ulcerative 
colitis or pseudomembranous colitis associated with broad spectrum 
antibiotics; discontinue promptly if abdominal distention, constipation, 
or ileus occurs. 
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Sensitivity Reactions 
Hypersensitivity 
Hypersensitivity reactions, including rash, reported. 
General Precautions 
Use of Fixed Combination 
When used in fixed combination with other agents, consider the 
cautions, precautions, and contraindications associated with the 
concomitant agents. 
Specific Populations 
Pregnancy 
Category B. 
Lactation 
Not known whether loperamide is distributed into human milk. Caution 
advised if used in nursing women.  
Pediatric Use: Not recommended for children <2 years of age. Use 
particular caution in young children due to greater variability of response 
to the drug; presence of dehydration, especially in younger children, may 
further influence variability of response. 
Not recommended for treatment of travelers’ diarrhea in infants, 
children, or adolescents with HIV infection. 
Children may be more sensitive to CNS effects than adults. 
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Hepatic Impairment: In patients with hepatic impairment, monitor 
closely for manifestations of CNS toxicity during therapy, since first-pass 
metabolism may be decreased. 
Common Adverse Effects 
Abdominal pain/distention/discomfort, constipation, drowsiness, 
dizziness, fatigue, dry mouth, nausea, vomiting, epigastric pain. 
Interactions for Loperamide Hydrochloride 
No drug interactions reported during clinical trials. 
Loperamide Hydrochloride Pharmacokinetics 
Absorption:99% 
Bioavailability: Peak plasma concentrations attained about 2.5 or 4–5 
hours after oral solution or capsules, respectively. Oral bioavailability of 
capsules and oral solution, as determined by AUC, is similar. 
Peak plasma concentrations of loperamide metabolites are reached 8 
hours following oral administration of capsules. 
Distribution  :Not known whether loperamide crosses the placenta or 
is distributed into milk. 
Elimination 
Elimination Route : Excreted principally in feces. 
Half-life: 10.8 hours (range 9.1–14.4 hours). 
Stability:well stabled 
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Storage:oral capsule 20 -250C 
Oral 
Capsules: Well-closed containers at 15–30°C. 
Solution:  20–25°C. 
Tablets:  20–25°C.Protect fixed-combination loperamide and simethicone 
caplets from light. 
Availability 
Capsules: 2 mg 
Solution: 1 mg/5 ml 
Tablets: 2 mg 
Tablets (chewable): 2 mg 
Indications and dosages 
➣ Acute diarrhea 
Adults: Initially, 4 mg , then 2 mg after each loose stool. Usual maintena
nce dosage is 4 to 8 mg . daily in divided doses,not to exceed 16 mg daily. 
Children ages 8 to 12 or weighing more than 30 kg (66 lb): Initially, 2
 mg P.O. t.i.d., then 1 mg/10 kg after each loose stool,not to exceed 6 mg
 daily 
Children ages 6 to 8 or weighing 20 to 30 kg (44 to 66 lb): Initially, 2 
mg P.O. b.i.d., then 1 mg/10 kg after each loose stool,not to exceed 4 mg 
daily 
CHAPTER IV                                                                                          DRUG PROFILE 
Department Of pharmaceutics,rvs college of pharmaceutical sciences Page 42 
 
Children ages 2 to 5 or weighing 13 to 20 kg (29 to 44 lb): Initially, 1 
mg P.O. t.i.d., then 1 mg/10 kg after each loose stool,not to exceed 3 mg 
daily 
➣ Acute diarrhea (treated with over-the-counter loperamide) 
Adults and children ages 12 and older: Twocaplets with 4 to 8 oz water
after first loose stool, then one caplet (with 4 to 8 ozwater) after each sub
sequent loose stool. Don't exceed four caplets in 24 hours. Or give equiva
lent dosage in liquid form. 
Children ages 9 to 11 who weigh 27 to 43 kg (60 to 95 lbs): One caple
t with 4 to 8 oz water after first loose stool, then ½caplet (with 4 to 8 oz w
ater) after each subsequent loose stool. Don't exceed three caplets in 24 
hours. Or give equivalent dosage in liquid form. 
Children ages 6 to 8 who weigh 22 to 27 kg (48 to 59 lbs): One caplet 
with 4 to 8 oz water after first loose stool, then ½ capletwith 4 to 8 oz 
waterafter each subsequent loose stool. Don't exceed two caplets in 24 
hrs. Or give equivalent dosage in liquidform. 
Children younger than age 6: Consult physician. 
➣ Chronic diarrhea 
Adults: Initially, 4 mg P.O., then 2 mg after each loose stool; reduce dosa
ge as tolerated. Don't exceed 16 mg daily for more than10 days. 
Precautions 
Use cautiously in: 
• hepatic disease 
• elderly patients 
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• pregnant or breastfeeding patients 
• children. 
Administration 
• Use patient's weight to determine appropriate dosage (especially in chil
dren). 
Route Onset Peak Duration 
P.O. 1 hr 2.5-5 hr 10 hr 
Adverse reactions 
CNS: drowsiness, dizziness 
GI: nausea; vomiting; constipation; abdominal pain, distention, or disco
mfort; dry mouth; toxic megacolon (in patients with acuteulcerative coli
tis) 
Other: allergic reactions 
Interactions 
Drug-
drug. Antidepressants, antihistamines, other anticholinergics: additive 
anticholinergic effects 
CNS depressants (including antihistamines, opioid analgesics, sedative-
hypnotics): additive CNS depression 
Drugherbs. Chamomile, hops, kava, skullcap, valerian 
Drug-behaviors. Alcohol use: increased CNS depression 
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5. METHODOLOGY 
5.1 MATERIALS 
TABLE NO 1 : List of Materials 
S.NO MATERIALS SUPPLIERS 
1 Loperamide MAYSA LABS PRIVATE LIMITED 
2 Propylene Glycol S.D fine chem. limited 
3 Poly Etylene Glycol 200 S.D fine chem. limited 
4 Poly Etylene Glycol 300 S.D fine chem. limited 
5 Poly Etylene Glycol 400 S.D fine chem. limited 
6 Poly Etylene Glycol 600 S.D fine chem. limited 
7 Tween 20 S.D fine chem. limited 
8 Tween 80 S.D fine chem. limited 
9 Span 20 S.D fine chem limited 
10 Span 80 S.D fine chem. limited 
11 Methanol S.D fine chem. limited 
12 HCl S.D fine chem. limited 
13 Microcrystalline Cellulose Saraswathi enterprises 
14 Aerosil Saraswathi enterprises 
15 Sodium Starch Glycollate Saraswathi enterprises 
 
Materials Used in Liquisolid Compacts 
Drug: 
Drugs which are poorly soluble or else insoluble in water. 
Examples of drugs that can be incorporated into liquisolid systems 
include: Digoxin, digitoxin, Prednisolone, Hydrocortisone, 
spironolactone, hydrochlorothiazide, polythiazide and other liquid 
medications such as chlorpheniramine, water insoluble vitamins, fish 
oil, etc.  
 
Non volatile Solvent: 
These may be hydrophilic or lipophilic in nature based on 
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selection of type of formulation like immediate or control release. 
Inert, high boiling point, preferably water miscible and not highly 
viscous organic solvent systems are most suitable as vehicles. Some 
of the materials are: Polyethylene glycol, Propylene glycol, Tween 80 & 
20, and Span 80 & 20. 
 
Carrier:  
These are preferred to be coarse and granular for acceptable 
flow. These are compress enhancers, relatively large, preferably 
porous particles possessing a sufficient absorption property which 
contributes in liquid absorption.  
Eg: Various grades of cellulose, lactose, sorbitol, etc. 
Coating Material:  
These are flow enhancing, very fine(10 nm to 5000 nm in 
diameter), highly adsorptive coating particles (eg. silica of various 
grades like Cab-O-SilM5, Aerosil200, Syloid244FPetc) contributes in 
covering the wet carrier particles and displaying a dry-looking powder 
by adsorbing any excess liquid. 
 
Super Disintegrants:   
 Most commonly used disintegrate are Sodium starch glycolate, 
Crosspovidone, Pumogel, etc. 
Chemicals Used: 
 Drug (loperamide), Methanol, HCl, propylene glycol (PG), PEG200, 
300, 400, 600,   span 80 & 20, tween 80 & 20, water , potassium 
bromide. 
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5.2 EQUIPMENTS 
 Table No. 2: Equipments Used 
S.NO EQUIPMENTS MANUFACTURER 
1.  
Digital balance SHIMAZDU 
2.  
Orbital Shaker LABINDIA 
3.  
FT-IR LABINDIA 
4.  
KBr Press LABINDIA 
5.  
Bulk Density Apparatus LABINDIA 
6.  
Mixer LABINDIA 
7.  
Tablet dissolution 
apparatus 
LABINDIA 
8.  
U.V visible 
spectrophotometer 
LABINDIA 
9.  
HPLC 
WATERS 
10. 
Hardness tester 
Monsanto hardness tester 
11. 
Disintegration test 
apparatus  
Campbell Electronics  
 
5.3 . METHODOLOGY: 
5.3.1 ESTIMATION OF LOPERAMIDE  
5.3.1.1 Development Of Calibration Curve For Loperamide: 
A) Loperamide was weighed accurately 10 mg using digital analytical  
balance and transferred in to100 ml of volumetric flask ,dissolve 
methanol and the final volume was made up to 100 ml with methanol 
to get a stock solution A. from the stock solution A, 10 ml was pipette 
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out in 50 ml volumetric flask and the final volume was made up to 50 
ml with hydrochloric acid to get a stock solution B. from the stock 
solution B, further dilution was  made with the hydrochloric acid in 10 
ml volumetric flask to get the solutions in the range of 0.2 to 1.8 µg/ml 
concentration  and absorbance was recorded at 214 nm against 
suitable blank using UV-visible spectrophotometer. 
B) Loperamide was weighed accurately 10 mg using digital analytical  
balance and transferred in to  100 ml of volumetric flask ,dissolve 
methanol and the final volume was made up to 100 ml with methanol 
to get a stock solution A. from the stock solution A, 10 ml was pipette 
out in 50 ml volumetric flask and the final volume was made up to 50 
ml with methanol to get a stock solution B. from the stock solution B, 
0.1ml was taken further dilution to 10 ml volumetric flask to get a 
solutions in the range of 0.2-1.8 µg/ml concentration  and absorbance 
was recorded at 214 nm against suitable blank using UV-visible 
spectrophotometer. 
5.3.2 Solubility studies: 
Determination of Solubility 
The solubility of loperamide in hydrochloric acid, methanol and two 
liquid vehicles tried to prepare the liquisolid systems, namely, water, 
tweens & spans, Polyethylene glycol 300, 400, 600, and Propylene 
glycol were studied by preparing saturated solutions of the drug in 
these solvents and analysing their drug content 
spectrophotometrically. Specially, loperamide was mixed in 7ml screw 
capped vials with such amounts of each of the above solvents in order 
to produce systems containing an excess of drug. The mixtures were 
shaken on an automatic test tube shaking machine for 48 hours and 
then settled for another 2 hours. The screw capped vials were 
centrifuged at 2500 rpm for further settling of un dissolved crystalline 
material and thereby obtaining a clear supernatant. After 
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centrifugation, accurately measured quantities of the filtered 
supernatant solutions were further diluted with methanol and 
analysed spectrophotometrically at 214 nm for their drug content. The 
results were extrapolated to determine the percent mg/ml of 
loperamide in its saturated solution with the solvents under 
investigation.  
* Drug concentration in liquid vehicle 
* Perecent in total weight of the tablet 
5.3.3   FORMULATION OF LIQUISOLID COMPACTS 
1. Model drug i s  initially dispersed in the non volatile solvent 
systems  
(Propylene glycol, PEG 400) termed as liquid vehicles with different 
drug: vehicle ratio. 
2. Then a mixture of carrier (Micro crystalline cellulose pH 102) was 
added to the   above liquid by Continuous mixing for a period of 10 to 
20 minutes in a mortar. 
3. Then to the above mixture coating material (Aerosil powder) was 
added and mixed thoroughly. The amount of carrier and coating 
materials added were based on the R value. 
4. To the above binary mixture disintegrant like cross povidone and 
other additives such as Glidant (magnesium stearate) are added 
according to their application and mixed in a mortar. 
5. The final blend was compressed. 
 
4.3.4 EVALUATION OF POWDER BLEND 
The prepared powder blend were subjected to evaluation as per 
the methods suggested in the Indian Pharmacopoeia like Bulk 
density, Tapped density, Hausner’s ratio, Angle of repose and car’s 
index. 
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a) Bulk density: 
Bulk density of Loperamide was determined by pouring gently 5.00gm 
through a glass funnel into 20 ml graduated cylinder. The volumes 
occupied by the samples were recorded. Bulk density was calculated 
as: 
 
 
b)Tapped density:   
Tapped density was determined by using LABINDIA density 
tester, which consists of a graduated cylinder mounted on a 
mechanical tapping device. An accurately weighed sample of powder 
was carefully added to the cylinder with the aid of a funnel. Typically, 
the initial volume was noted, and the sample is then tapped (50, 
100,150 or 250 tapping) until no further reduction in volume is noted 
or the percentage of difference is not more than 2%. 
A sufficient number of taps should be employed to assure 
reproducibility for the material in question. Volume was noted and 
tapped density is calculated using following formula. 
 
 
c) Compressibility Index and Hausner’s ratio: 
In recent years the compressibility index and the closely related 
Hausner’s ratio have become the simple, fast, and popular methods of 
predicting powder flow characteristics. Both the compressibility index 
and the Hausner’s ratio were determined by using bulk density and 
the tapped density of a powder.  
 
 
Bulk density = weight of sample in gram /volume occupied by the sample 
Tapped density = Wt. of sample in gm / Tapped volume 
100
density  Tapped
density Bulk desnity Tapped
 index  sCarr'   
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d) Angle of repose:  
 The angle of repose of the powder blend was determined by using 
funnel method. The accurately weighed powder was taken in a funnel. 
The height of funnel was adjusted in such a way that the tip of the 
funnel just touched the apex of the heap of the powder. The diameter 
of the powder cone was measured and angle of repose was calculated 
by using the equation. 
 
Tan θ = h/r 
Where , 
h and r are the height of pile and radius of the pile. 
 
       
 TABLE NO 3:    The relation between angle of repose and flow 
properties 
Angle of repose θ Flow 
<25 Excellent 
25-30 Good 
30-40 Passible 
>40 Very poor 
 
TABLE.NO 4:  Flow property:  (Relation of flow property with HR & CI) 
 
 
 
 
 
 
 
Compressibility 
Index (%) 
Flow  Character                    Hausenr’s Ratio 
10 Excellent 1.00–1.11 
11–15 Good 1.12–1.18 
16–20 Fair 1.19–1.25 
21–25 Passable 1.26–1.34 
26–31 Poor 1.35–1.45 
32–37 Very poor 1.46–1.59 
>38 Very, very poor >1.60 
Hausenr’s Ratio = Tapped Density / Bulk Density 
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5.3.5. CHARACTERIZATION OF LOPERAMIDE LIQUISOLID 
COMPACTS: 
Compatibility Studies: Fourier Transform –Infrared spectroscopy (FT-
IR) 
The samples of, liquisolid compacts of physical mixture were prepared 
with KBr in the ratio of 1 : 2 in the form of KBr pellets and subjected 
for scanning from 4000cm-1 to 400cm-1 using FT-IR 
spectrophotometer  .the peaks are appeared . 
 
5.3.6 FORMULATION OF IMMEDIATE RELEASE TABLETS OF 
LOPERAMIDE LIQUISOLID COMPACTS 
1. The Lopramide drug was  g i f t  sample  f rom MAYSA LABS 
PVT LTD.  
     The drug was dispersed in the non volatile solvent systems 
(Propylene glycol)  
      Termed as liquid vehicles with different drug: vehicle ratio. 
2. Then a mixture of carrier (Micro crystalline cellulose ) was added to 
the   above liquid by Continuous mixing for a period of 10 to 20 
minutes in a mortar until free flow is obtained. 
3. Then to the above mixture coating material (Aerosil powder) was 
added and mixed thoroughly. The amount of carrier and coating 
materials added were based on the R value. 
4. To the above binary mixture disintegrants like cross povidone and 
other SSG  remaining additives such as Glidant (magnesium stearate) 
are added according to their application and mixed in a mortar. 
5. The final blend was compressed by using 9mm punch. 
 
 
 
 
CHAPTER V                                                                                    METHODOLOGY 
Department Of Pharmaceutics,rvs college of pharmaceutical sciences Page 53 
 
 
 
TABLE NO 5: Formulation Of Loperamide  Liquisolid Compacts 
 
 
Formul
ations 
 
Drug 
conc.in 
PG(%w/w) 
 
R 
 
Lf 
 
MCC 
(mg) 
 
 
Aerosol 
(mg) 
 
 
Sodium 
starch 
glycolate 
 
Total 
Tablet 
weight (mg) 
F1 2 19.2 0.006 300 15.5 40 380 
F2 2 10.5 0.009 210 20 40 320 
F3 2 20 0.008 200 10 40 300 
F4 4 5.6 0.017 225 40 40 330 
F5 4 11 0.018 220 20 40 260 
F6 4 12 0.017 235 25 40 280 
F7 6 10 0.023 260 24 40 310 
F8 6 20 0.024 250 12.5 40 330 
F9 6 15 0.025 240 15 40 310 
 
Excipient ratio, R=Q/q.    Q, weight of carrier;  q, weight of 
coating material. 
Liquid load factor, Lf   = W/Q . W, weight of liquid medication. 
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5.3.7. EVALUATION OF TABLETS: (POST COMPRESSION 
PARAMETER) 
1. Weight variation. 
2. Hardness. 
3. Friability. 
4. Disintegration Time. 
5. Dissolution. 
6. Assay (% of drug content). 
7. Compatibility studies. 
8.  Powder X-Ray diffraction studies.  
9. Stability studies. 
1.  Weight Variation: 
20 intact tablets were selected randomly and weighed ,the average 
weight was calculated. Individual weight of each tablet was 
determined. According to USP, none of the individual tablet weight 
should be less than 90% and more than 110% of the average weight. 
2.Hardness:   
Take 10 tablets from the sample given for analysis, test the Hardness  
in Kg/Cm2  for each tablet  and note down the results.  Calculate the 
average of the 10 readings and report the average result.   
 Acceptance criteria:  Not less than 4.0 Kg/cm2. 
3.   Friability (core tablets): 
Take 13 tablets from the sample given for analysis and de-dust.  
Weigh the tablets and note down the weight.  Place the tablets in the 
drum of the friability apparatus and set the apparatus rotation time 
for 4 minutes (100 revolutions).  Operate the instrument for the 
specified time or for the rpm.  Take out the tablets and de-dust.  
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Weigh the tablets and calculate the friability by the following 
formulae.  
 
Friability (%) =    
          (Initial weight of the tablets – Final weight of the tablets)   x 100             
              
                                      Initial weight of the tablets 
             
Acceptance criteria:  Friability is not more than 1.0 % 
 
4.  Disintegration Time: 
          
Fill the beakers with  water and switch on the Apparatus and wait for 
some time to reach the desired temperature (37 0 C).When the 
apparatus reaches to the desire temperature, the siren is coming from 
the apparatus.  Place the 6 tablets in each case of the basket.  Press 
start for disintegration and observe the tablets for disintegration. Note 
down the time of the last tablet for complete disintegration (No tablet 
fragments should remain on the mesh of the cases of the basket) 
Acceptance criteria:  Not more than 30 minutes. 
 
5. Dissolution Studies (In Vitro Drug Release Studies): 
The Model drug release from different formulations was determined 
using aUSP-type2 (paddle type) apparatus under sink condition. The 
dissolution medium was 900ml 0.01M HCl. 37 ± 0.5°C; at 50rpm, to 
simulate in vivo conditions. The formulation prepared was subjected 
to dissolution tests for 2hrs. Sample (5ml) was withdrawn at 
predetermined time intervals ( 5, 10, 15, 30, 45, 60, 90 & 120), 
filtered through Whatmann filter paper and replaced by an equal 
volume of dissolution medium.  
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Drug content in the dissolution sample was determined by UV 
spectrophotometer at 214 nm. 
Apparatus       : USP-2, paddle method 
Dissolution Medium : 0.01 N HCl 
rpm        : 50  
Time intervals       : 5, 10, 15, 30, 45, 60, 90 & 120 
Temperature      : 37 ± 0.50 C 
 
6. Assay: 
         Each un coated Tablet Contains 
Loperamide      BP  2 mg 
 
Method of analysis                    :   HPLC   
 
Chromatographic Conditions    : 
 
Column                                      : C18 (4.6 X 15 cm) BDS 
 
Wave length                              : 214 nm 
 
Flow rate                                    : 1.2 ml   
 
Mobile phase: Buffer: Acetonitrile (50: 50) 
Buffer: Weigh and transfer 2.95 gms of Potassium Di Hydrogen 
Orthophosphate into a 1000 ml VF.  Add about 500 ml of Water 
and shake well to dissolve.  Add 0.53 gms of Di potassium 
Hydrogen Orthophosphate dissolve and makeup the volume with 
Water.  
 
Standard Preparation:  Weigh about 25 mg of working standard 
transfer to 25 ml VF and make up with Mobile Phase. Transfer 2 ml  
of this solution to 25 ml and make up with Mobile Phase.. 
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Test Preparation:  Weigh equivalent to about 20 mg of the active 
substance and transfer to a 50 ml VF , shake well to dissolve and 
make up the volume with Mobile Phase.   Filter the solution and reject 
the first few ml of the filtrate.   Transfer 5 ml of the filtrate into a 25 
ml VF and makeup the volume with Mobile Phase. 
 
Calculation:  Assay = % Tab. 
 Test Area       Std Wt.         2            50          25      Std. purity   100 
 ------------- X ---------- X -------X-----------X -----  X ------------X ------ X Avg. Wt. = 
Std Area          25              25          Test Wt      5            100            2 
 
  Acceptance criteria:  Not less than 90 % and not more than  110 % 
of the label claim. 
7. Compatability studies: 
Compatibilitystudies were carried out using Fourier Transform Infra
red spectroscopy to detect any possible interaction of loperamide 
with the excipient used in the formulation.  
The FTIR spectra of the formulations were compared with the 
FTIR spectra of the pure drug.(400 cm-1 - 4000cm-1). The results 
indicated that the characteristic absorption peaks due to pure 
loperamide have appeared in the formulated liquisolid compact, 
without any significant change in their position after successful 
encapsulation. 
8.Powder Analysis XRD: 
Powder Analysis of loperamide, physical mixture and liquisolid 
formulation were studied  by using X-ray diffractometer .   
X-ray diffraction is based on constructive interference of 
monochromatic X-rays and a crystalline sample. These X-rays are 
CHAPTER V                                                                                    METHODOLOGY 
Department Of Pharmaceutics,rvs college of pharmaceutical sciences Page 58 
 
generated by a cathode ray tube, filtered to produce monochromatic 
radiation, collimated to concentrate, and directed toward the sample. 
The interaction of the incident rays with the sample produces 
constructive interference (and a diffracted ray) when conditions 
satisfy Bragg's Law (nλ=2d sin θ). This law relates the wavelength of 
electromagnetic radiation to the diffraction angle and the lattice 
spacing in a crystalline sample. These diffracted X-rays are then 
detected, processed and counted. By scanning the sample through a 
range of 2θangles, all possible diffraction directions of the lattice 
should be attained due to the random orientation of the powdered 
material. Conversion of the diffraction peaks to d-spacings allows 
identification of the mineral because each mineral has a set of unique 
d-spacings. Typically, this is achieved by comparison of d-spacings 
with standard reference patterns. 
All diffraction methods are based on generation of X-rays in an X-ray 
tube. These X-rays are directed at the sample, and the diffracted rays 
are collected. A key component of all diffraction is the angle between 
the incident and diffracted rays. Powder and single crystal diffraction 
vary in instrumentation beyond this. 
9. Stability studies: (Accelerated Stability Studies: Temperature 
40 ± 2 ͦC & Relative Humidity 75 ± 5%) 
The stability studies were carried out according to ICH guidelines 
by exposing the formulations F1 to F9 in their final packing mode 
to the temperature 40 ± 2  ͦC and relative humidity 75 ± 5% in 
programmable environmental test chamber. Aliquot were 
withdrawn at 30 and 60 days and analyzed for change in drug 
content, hardness, friability, disintegration time, and in-vitro 
dissolution profile. 
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5.0 RESULTS 
TABLE N0:6 Standard Calibration Curve of Loperamide In 0.01NHCl at 
(λmax=214nm) 
S.NO Concentration µg/ml Absorbance 
1 0.2 0.1347 
2 0.4 0.2481 
3 0.6 0.3541 
4 0.8 0.4645 
5 1.0 0.5643 
6 1.2 0.6723 
7 1.4 0.7892 
8 1.6 0.8723 
9 1.8 0.9921 
 
 
Standard graph of Loperamide in 0.01N HCl at (λmax = 214nm) 
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TABLE NO 7: Standard Calibration Curve of Loperamide In Methanol At  
       (λmax = 214nm) 
             
S.NO Concentration µg/ml Absorbance 
1 0.2 0.1321 
2 0.4 0.2489 
3 0.6 0.3511 
4 0.8 0.4621 
5 1.0 0.5689 
6 1.2 0.5689 
7 1.4 0.7661 
8 1.6 0.8801 
9 1.8 0.9854 
 
Standard graph of Loperamide in Methanol at    (λmax = 214nm) 
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TABLE NO 8: Preformulation Studies 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Form
ulatio
ns  
Angle of 
repose   
Bulk 
density(gm/ml) 
Tapped 
density(gm/ml
) 
Carr’s index 
(%) 
Hausner’s 
ratio 
F1 28  ± 0.21 0.22  ± 0.02 0.25  ± 0.05 12.53  ± 0.12 1.13  ± 0.11 
F2 30  ± 0.20 0.25  ± 0.03 0.27  ± 0.01 7.40  ±  0.29 1.08  ± 0.23 
F3 29  ± 0.25 0.22  ± 0.05 0.25  ± 0.01 12.53  ± 0.19 1.13  ± 0.25 
F4 28  ± 0.12 0.23  ±  0.01 0.26  ± 0.03 12.69  ± 0.17 1.13  ± 0.12 
F5 27  ± 0.16 0.22  ± 0.07 0.26  ± 0.07 16.34  ± 0.21 1.18  ± 0.16 
F6 28  ± 0.30 0.23  ± 0.09 0.25  ± 0.04 8.00   ± 0.15 1.08  ± 0.12 
F7 32  ± 0.20 0.25  ± 0.01 0.28  ± 0.01 10.74  ± 0.32 1.12  ± 0.20 
F8 30  ± 0.39 0.22  ±  0.03 0.27  ± 0.04 18.51  ± 0.24 1.22  ± 0.24 
F9 28  ± 0.45 0.20  ±  0.04 0.26  ± 0.02 23.07  ± 0.31 1.30  ± 0.11 
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FT-IR STUDIES OF PHYSICAL MIXTURE WITH DRUG 
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FT-IR STUDIES OF PURE DRUG: LOPERAMIDE   
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FT-IR SPECTRA OF OPTIMIZED FORMULA: ( F2 ) 
 
 
 
 
 
 
  
 
 
 
 
 
 
TABLE NO 9: Evaluation Parameters:  
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Formulations 
Weight 
Variation 
Hardness 
kg/cm2 
Disintegration 
time (min) 
Friability% 
% of Drug 
content 
(%w/w) 
F1 323 ± 3.0 4.5 ± 0.02 3 0.79 96.5 
F2 292 ± 2.5 3.0 ± 0.05 4 0.65 98.2 
F3 302 ± 3.11 3.0 ± 0.01 4 0.53 92.9 
F4 327 ± 4.7 4.0 ± 0.03 3 0.56 94.00 
F5 263 ± 2.14 4.5 ± 0.04 3 0.77 95.9 
F6 243 ± 3.23 3.5 ± 0.03 5 0.71 97.43 
F7 315 ± 7.43 3.0 ± 0.01 4 0.39 92.24 
F8 333 ± 3.56 3.0 ± 0.01 4 0.48 90.09 
F9 302 ± 1.98 3.5 ± 0.03 3 0.82 94.89 
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TABLE NO 10 :Invitro% Drug Release  Profile  Data Of Loperamide Liquisolid 
Compacts 
 
Time 
(min) 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
5 
 
34.50±0.9 
 
40.98±1.0 
 
42.06±1.09 
 
23.00± 0.9 
 
45.06 ± 0.9 
 
33.02 ± 1.20 
 
29.07±  0.8 
 
30.96 ±0.08 
 
24.43 ± 0.8 
 
10 
 
37.44±1.2 
 
52.89±1.0 
 
49.0±1.04 
 
50.10± 0.7 
 
49.92 ± 1.4 
 
34.93 ± 1.12 
 
31.01 ± 0.9 
 
33.98 ± 0.6 
 
30.67 ± 0.9 
 
15 
 
47.66±0.8 
 
86.81±1.0 
 
54.40±1.20 
 
52.66± 0.9 
 
51.09 ± 1.3 
 
44.88 ± 1.05 
 
32.65 ± 0.9 
 
39.25 ±1.01 
 
49.05 ± 0.9 
 
30 
 
52.90± 0.8 
 
89.76± 0.9 
 
58.99±1.15 
 
58.50± 1.1 
 
53.22±1.21 
 
50.56 ± 1.04 
 
38.36±1.24 
 
40.61 ±1.04 
 
53.01± 0.7 
 
45 
 
72.89±1.10 
 
90.50±1.0 
 
69.35±1.6 
 
60.01± 0.9 
 
59.24±1.02 
 
52.68 ± 1.09 
 
40.74±1.02 
 
44.17  ± 0.9 
 
58.90±1.00 
 
60 
 
74.38±0.7 
 
96.57± 1.1 
 
85.76±0.9 
 
67.71± 0.5 
 
59.38 ± 1.3 
 
60.09 ± 1.10 
 
49.27±1.10 
 
50.26 ± 0.8 
 
61.96±1.03 
 
90 
 
85.23±0.4 
 
97.8± 1.00 
 
87.81±1.12 
 
72.30± 0.3 
 
60.33 ± 0.7 
 
67.8 ± 1.03 
 
54.93±1.42 
 
50.37 ±1.12 
 
69.87 ± 0.9 
 
120 
 
86.79±1.3 
 
98.27± 0.9 
 
88.44±0.9 
 
83.4 ± 0.9 
 
66.22 ± 0.9 
 
70.31 ± 1.32 
 
55.48 ± 1.3 
 
51.52 ±1.01 
 
72.08 ± 0.9 
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TABLE NO 11: Optimized Formula Compared With the Pure Drug And 
Marketed Product 
Time 
(min) 
Optimized 
Formula F2 
Marketed 
drug 
Pure drug 
 (loperamide) 
0 0 0 0 
5 40.98 18.8 9.99 
10 52.89 35.83 10.5 
15 86.81 54.57 15.21 
30 89.76 60.64 17.18 
45 90.5 79.66 23.98 
60 96.57 84 30.2 
90 97.8 98 33.45 
120 98.21 102.89 55.01 
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POWDER ANALYSIS:  (XRD)    X-Ray Diffraction :Pure drug: 
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Optimized formula F2: 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI                                                                        RESULTS AND DISCUSSION  
 
Department Of pharmaceutics, rvs college of pharmaceutical science                               72 
 
 
 Physical mixture,  
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STABILTY STUDIES: 
  
        TABLE NO 13: Temperature 40 ± 20C & Relative Humidity 75±5%. 
S.No Time Intervals Drug Content % 
1 Initial 99.2 
2 1month 98.90 
3 2 Months 98.07 
4 3 Months 97.84 
 
 
6.0. DISCUSSION: 
6.1. Calibration Curve Of Loperamide: 
The calibration curve of Loperamide was obtained in the range of 0.2 to 1.8 
µg at wavelength of 214 nm. It  has shown good linearity with a regression 
coefficient of 0.999. (R2 value) 
6.2.Solubity Studies:  
The solubility of loperamide in hydrochloric acid, methanol ,water, tweens 
& spans, Polyethylene glycol 300, 400, 600, and Propylene glycol were studied by 
preparing saturated solutions of the drug in these solvents and analysing 
their drug content spectrophotometrically. At 214 nm for their drug content. 
The results were extrapolated to determine the percent mg/ml of loperamide 
in its saturated solution with the solvents under investigation.  
Among all these vehicles loperamide was highly soluble in propylene glycol 
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149.65mg/ml. 
6.3. Evaluation Parameters For Immediate Release Tablets of Loperamide 
6.3.1. Pre Compression Parameters: 
The values for Angle of Repose were found to be in the range of 28 ͦ-32 ͦ, Bulk 
Densities and Tapped Densities of various formulations were found to be in 
the range of 0.20 ± 0.006 to 0.25 ± 0.007 (g/cc) and 0.25 ± 0.006 to 0.28 ± 
0.005 (g/cc) respectively.  
Carr’s Index of the prepared blends falls in the range of 7.4% to 23.07%. 
from the result it was concluded that the powder blends had good to fair flow 
properties and these can  be used for tablet manufacture. 
6.3.2. Post Compression Parameters: 
Hardness: 
Hardness of the three tablets of each batch was checked by using Monsanto 
hardness tester. 
The results showed that the hardness of the tablets was in the range of 3.0 to 
4.5 Kg/cm2. 
Weight variation Test: 
Tablets of each batch were subjected to weight variation test, difference in 
weight and percent deviation was calculated for each tablet. 
Friability: 
Tablets of each batch were evaluated for percentage friability and the data’s 
were shown in above. The average friability of all the formulations lies in the 
range of 0.39 % to 0.82% which was less than 1% as per official requirement 
of IP indicating a good mechanical resistance of tablets. 
In Vitro Disitegration Time: 
Tablets of each batch were evaluated for In vitro Disintegration Time   
The Results Showed That The Disintegration Time Of prepared Tablets Were 
In The Range Of 3 Mins To 5 Mins. 
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In Vitro Dissolution Studies: 
Finally, Tablets were evaluated for In Vitro dissolution studies in simulated 
gastric fluid and the results were shown in table no: 11 
Formulation F1 showed 86.79% of drug release with 4% SSG, Aerosil 15.5 
mg, Formulation F2 showed 98.27% of drug release with the 4% SSG Aerosil 
20 mg,  F3 which contain 4% SSG, 10mg of Aerosil showed 88.44% of drug 
release, Formulation F4 showed 83.40% of drug release with 4% SSG & 
Aerosil 40 mg, Formulation F5 showed 66.22% of drug release with 4% SSG 
& Aerosil 20 mg, Formulation F6 showed 70.31% of drug release with the 4% 
SSG& Aerosil 25 mg, Formulation F7 showed 55.48% of drug release with the 
4% SSG& Aerosil 24 mg, Formulation F8 showed 51.52% of drug release with 
the 4% SSG & Aerosil 12.5 mg and  finally F9 showed 72.08% of drug release 
with the 4% SSG & Aerosil 15 mg, This result exhibit direct relationship 
between concentration of propyleneglycol and concentration of Aerosil. Among 
various formulations the tablets of batch F2 prepared with 2% Propylene 
glycol and 20 mg Aerosil showed within 15 minutes 85% of drug will be 
released. 
6.4. POWDER X-RAY DIFRACTION: 
Powder Analysis of  loperamide, physical mixture and liquisolid formulation 
were studied using X-ray diffractometer .     
 
6.5. Stability studies: 
Stability studies were carried out for the selected formulation F2 and the 
results were shown in table no: 12. The result showed that there was no 
significant difference in the drug content, disintegration time, hardness and 
friability at various sampling intervals. The In-vitro dissolution profiles were 
super impossible which confirms the stability of the product. 
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The study conducted on formulation and evaluation of liquisolid compacts 
of loperamide for the Effective management of Anti-diarrheal with the 
following conclusion: 
The tablets were prepared by compression of loperamide immediate release. 
The FT- IR study conducted using combination of drugs and excipients 
concluded that the drug and polymers where compatible. 
The pre compression parameters of the powder blends used for preparation 
of loperamide liquisolid compacts were in acceptable range of 
pharmacopeial specification with excellent flow and good compressibility.  
Loperamide liquisolid compacts was formulated as immediate release 
tablets using sodium starch glycolate as disintegrants in increased 
concentration by direct compression method. The loperamide tablets are 
evaluated for post compression parameters suggested that hardness, 
thickness, weight variation and friability were in acceptable limit with good 
handling properties. All the loperamide immediate release formulations 
where rapidly disintegrates in less than 5min. All the formulated loper 
amide liquisolid compacts showed drug content of more than 92%.  
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CONCLUSION AND SUMMARY 
7.0. CONCLUSION  
The Following conclusions were drawn from the Liqisolid 
compacts studies: 
The solubility studies of Loperamide in presence of  Propylene Glycol 
was high when compared with PEG and Tweens & spans. 
The liquisolid technique was found to be a promising approach for 
improving the dissolution of poorly soluble drugs like lopermide. 
The Dissolution of loperamide was significantly increased in liquisolid 
formulation compared to the marketed product. The IR spectra 
indicate there was no interaction between the drug and excipients. 
The increased dissolution rate may be due to increased wetting and 
increased surface area of the particles. 
From the XRD, FT-IR, Drug content & In Vitro dissolution studies of 
loperamide liquisolid compacts it was concluded that the formulation 
F2 is the best formulation.  
The following conclusions were drawn from the Liquisolid 
compacts formulated to tablets: 
The powder blend was subjected to various physical characteristics 
such as bulk density, tapped density, Hausner’s ratio, compressibility 
index. The powder was compressed and the core tablets were 
evaluated for weight variation, hardness, disintegration time, drug 
content, dissolution studies, powder analysis like XRD, FT-IR studies 
& stability studies is concluded the best formulation is F2.  
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7.1.0. SUMMARY  
The major problem in oral drug formulations is low and enteric 
bioavailability, which mainly results from poor aqueous solubility. 
Liquisolid compacts is the techniques are the most attractive 
processes to improve solubility of poorly soluble drugs .  
Loperamide hydrochloride an oral Anti-diarreheal agent used for the 
treatment of diarrheal. 
Loperamide is a Piperidine derivative. Loperamide is an opioid-
receptor agonist and acts on the μ-opioid receptors in the myenteric 
plexus of the large intestine. 
 Slows intestinal motility and affects water and electrolyte 
movement through the bowel.Inhibits peristaltic activity by a direct 
effect on circular and longitudinal muscles of the intestinal wall. 
 Prolongs the transit time of intestinal contents; reduces fecal 
volume, increases fecal viscosity and bulk density, and diminishes 
loss of fluid and electrolytes. 
 Inhibits peristalsis of intestinal wall musculature and intestinal co
ntents. Also reduces fecal volume, increases fecal bulk, andminimi
zes fluid and electrolyte loss. 
Here the solubility of Loperamide is enhanced by liquisolid compacts 
with propylene glycol as liquid medication. Then the formed liquisolid 
compact is characterized and evaluated by FT-IR , drug content and  
In Vitro  dissolution studies. 
Among the various liquisolid compacts were prepared, the formulation 
F2 i.e., the liquisolid compacts of Loperamide with PG 2% shows 
faster dissolution rate. 
The prepared tablets of LOPERAMIDE were evaluated for 
precompession parameters like angle of repose, bulk density, tapped 
density, carr’s index and post compression parameters like hardness, 
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friability, weight variation, drug content, In Vitro disintegration time 
and In Vitro dissolution studies. 
Accelerated stability studies was carried out for selected formulations 
F2 which showed no significant difference in the drug content, 
disintegration time , hardness, friability and In vitro dissolution 
studies which confirm the stability of product. 
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